We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-6.04%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.45B
AUM Growth
-$206M
Cap. Flow
+$38.7M
Cap. Flow %
2.66%
Top 10 Hldgs %
69.2%
Holding
57
New
2
Increased
7
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$40.5M
2
GERN icon
Geron
GERN
+$17M
3
VERA icon
Vera Therapeutics
VERA
+$14.3M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.48M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.6M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$12.8M
2
EPIX
ESSA Pharma
EPIX
+$10.6M
3
WHWK
Whitehawk Therapeutics
WHWK
+$10.2M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.31M
5
MREO
Mereo BioPharma
MREO
+$4.02M

Sector Composition

Rank Sector Weight
1 Healthcare 84.74%
2 Financials 11.77%
3 Materials 3.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
1
Harmony Biosciences
HRMY
$2.07B
$222M 15.31%
4,570,148
-314,193
-6% -$12.8M
NFH
2
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$171M 11.77%
14,300,000
– –
TIL icon
3
Instil Bio
TIL
$49.4M
$134M 9.24%
624,339
– –
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$108M 7.45%
6,431,940
+141,113
+2% +$2.09M
SRRA
5
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$107M 7.35%
3,329,511
+1,412,437
+74% +$40.5M
ALXO icon
6
ALX Oncology
ALXO
$268M
$71.3M 4.91%
4,220,048
– –
ASND icon
7
Ascendis Pharma A/S
ASND
$16.7B
$51.9M 3.58%
442,502
– –
AMRS
8
DELISTED
Amyris Inc.
AMRS
$50.8M 3.5%
11,642,195
– –
TARS icon
9
Tarsus Pharmaceuticals
TARS
$2.57B
$50.2M 3.46%
2,987,331
– –
SVA
10
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 2.63%
5,900,000
– –
VTYX
11
DELISTED
Ventyx Biosciences
VTYX
$26.1M 1.8%
1,921,726
+130,451
+7% +$1.74M
VRDN icon
12
Viridian Therapeutics
VRDN
$2.15B
$24M 1.66%
1,300,000
– –
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$22.6M 1.56%
1,533,559
– –
CLDX icon
14
Celldex Therapeutics
CLDX
$2.79B
$21.4M 1.47%
628,356
+143,903
+30% +$4.6M
GERN icon
15
Geron
GERN
$930M
$20.7M 1.43%
+15,238,095
New +$17M
AVDL
16
DELISTED
Avadel Pharmaceuticals
AVDL
$20.1M 1.38%
2,937,093
– –
RLMD icon
17
Relmada Therapeutics
RLMD
$549M
$19.1M 1.31%
705,882
-176,470
-20% -$3.65M
IMPL
18
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$18.4M 1.27%
2,884,789
– –
GTH
19
DELISTED
Genetron Holdings Limited ADS
GTH
$16.2M 1.12%
2,470,526
+357,239
+17% +$3.91M
IOBT
20
DELISTED
IO Biotech
IOBT
$16M 1.1%
3,015,545
– –
VERA icon
21
Vera Therapeutics
VERA
$2.39B
$15.7M 1.08%
+666,666
New +$14.3M
ACRS icon
22
Aclaris Therapeutics
ACRS
$744M
$15.5M 1.07%
898,631
-22,351
-2% -$305K
COGT icon
23
Cogent Biosciences
COGT
$6.95B
$14.4M 0.99%
1,920,941
– –
KDNY
24
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$14.3M 0.98%
872,151
– –
VRNA
25
DELISTED
Verona Pharma
VRNA
$13.7M 0.94%
2,749,918
– –
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Vivo Capital held 57 positions worth $1.45B, down 12% from $1.66B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Vivo Capital's Q1 2022 filing shows 2 new, 7 increased, 7 reduced and 3 closed positions. Its largest new stake was Geron: 15,238,095 shares worth $20.7M. The largest sale was Harmony Biosciences, an estimated $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q1 2022 buy was Geron: 15,238,095 shares worth $20.7M.
  • Vivo Capital added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $40.5M increase.
  • Vivo Capital's biggest Q1 2022 reduction was Harmony Biosciences, cutting an estimated $12.8M.
  • Vivo Capital fully exited ESSA Pharma in Q1 2022, selling an estimated $10.6M.
  • Vivo Capital's ten largest holdings make up 69% of its $1.45B portfolio in Q1 2022.
  • Vivo Capital opened 2 new positions and closed 3 in Q1 2022.
  • Vivo Capital's portfolio value fell 12% quarter-over-quarter to $1.45B.

Based on Vivo Capital's 13F filing for Q1 2022, filed 13 May 2022.